Wedbush Downgrades Audentes Therapeutics (BOLD) to Neutral Following Acquisition

December 3, 2019 6:49 AM EST
Get Alerts BOLD Hot Sheet
Price: $59.97 --0%

Rating Summary:
    1 Buy, 14 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 18 | Down: 11 | New: 8
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Wedbush analyst David Nierengarten downgraded Audentes Therapeutics (NASDAQ: BOLD) from Outperform to Neutral with a price target of $60.00 (from $44.00).

For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.

Shares of Audentes Therapeutics closed at $28.61 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst PT Change, Downgrades